控股权变更完成 新康华生物在成都揭牌

Core Insights - The completion of the acquisition of Kanghua Biological by Shanghai Biopharmaceutical M&A Fund through Wankexin Biological was marked by a ceremony in Chengdu on November 27, 2025 [1] Group 1: Company Developments - New Kanghua Biological aims to introduce fresh capital to drive development, indicating a strategic shift following the acquisition [3] - The new chairman of Kanghua Biological, Liu Dawei, emphasized the company's established reputation and the importance of capital and industry integration for future growth [4] - Strategic agreements were signed with several partners and professional institutions to support market layout and channel expansion for New Kanghua Biological [4] Group 2: Industry Context - The president of the China Vaccine Industry Association highlighted the opportunities in China's vaccine industry, noting an improving policy environment that could benefit New Kanghua Biological [3] - The collaboration between Shanghai and Chengdu in the biopharmaceutical sector is expected to enhance research and development, clinical practices, and industrial cooperation [4]